STM 434: Phase I started

Atara began an open-label, dose-escalation, U.S. Phase I trial to evaluate 0.25-4 mg/kg IV STM 434 every 28 days in about 66 patients. The trial will determine the maximum tolerated dose (MTD) in pati...